Belite Bio, Inc
BLTE
Hisse Senetlerindeki Sıralama
#2984
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Hisse Fiyatı
$152.78
Piyasa Değeri
$6.15B
Değişim (1 gün)
-1.08%
Değişim (1 yıl)
66.06%
Ülke
US
Ticaret Belite Bio, Inc (BLTE)
Kategori
Healthcare
Belite Bio, Inc (BLTE) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $154.24 - 2026-10-01
Gün sonu en düşük fiyat: $10.59 - 2022-04-01
Gün sonu en düşük fiyat: $10.59 - 2022-04-01
Belite Bio, Inc için hisse fiyatı geçmişi: 2022 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 1.17% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
